Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion type Assertion NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_head.
- NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion description "[In addition, the ERK1/2-binding IQGAP1 WW domain peptide disrupted IQGAP1-ERK1/2 interactions, inhibited RAS- and RAF-driven tumorigenesis, bypassed acquired resistance to the BRAF inhibitor vemurafenib (PLX-4032) and acted as a systemically deliverable therapeutic to significantly increase the lifespan of tumor-bearing mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_provenance.
- NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion evidence source_evidence_literature NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_provenance.
- NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion SIO_000772 23603816 NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_provenance.
- NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion wasDerivedFrom befree-2016 NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_provenance.
- NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_assertion wasGeneratedBy ECO_0000203 NP1071117.RAdkG4nSPYX3uMrc2BJrJ3hcL6XVcgv17mrTqvZBwhQgs130_provenance.